Blocking CXCL12 signalling has been implicated in the success of immune checkpoint inhibitors in preclinical models and a clinical trial of pancreatic ductal adenocarcinoma, suggesting that intratumoural levels of CXCL12 may have implications within the clinical setting of treatment for patients [25]. The gene discussed is CXCL12; the disease is pancreatic ductal adenocarcinoma.